Tactile Systems Technology Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue grew 23% year-over-year to $75.3 million, with strong gains in both lymphedema and airway clearance segments. Gross margin expanded to 76.5%, and adjusted EBITDA improved to $3.7 million. Full-year guidance was raised, reflecting confidence in commercial execution and the LymphaTech acquisition.
Fiscal Year 2025
-
Delivered strong 2025 results with 12% revenue growth, margin expansion, and record Q4 performance. 2026 guidance anticipates 8%-11% growth, factoring in a short-term Medicare prior authorization headwind. Acquisition of LymphaTech and new product launches support long-term growth.
-
Strong Q3 results and market leadership in both lymphedema and airway clearance were driven by strategic investments, salesforce transformation, and product innovation. Regulatory clarity and new clinical data are expected to further boost growth, with double-digit expansion anticipated in both core segments.
-
Q3 2025 saw 17% revenue growth, margin expansion, and strong gains in both lymphedema and airway clearance segments. Guidance for 2025 was raised, supported by operational investments, new product launches, and favorable Medicare policy changes.
-
Q2 revenue rose 7.8% YoY to $78.9M, with strong airway clearance growth and improved gross margin, though adjusted EBITDA declined due to planned investments. FY2025 guidance was raised modestly, reflecting confidence in execution but caution around scaling and tech rollouts.
-
A large, underserved market in lymphedema and bronchiectasis is being addressed through innovative, portable devices, robust clinical evidence, and digital patient engagement. Strategic investments in technology, sales, and education support profitable growth and expanded market access.
-
A $10 billion addressable market in lymphedema and bronchiectasis is being targeted with innovative, tech-enabled therapies and a robust clinical evidence base. Strategic investments in sales, technology, and patient engagement are set to drive continued growth and market leadership.
-
Q1 revenue was flat year-over-year as lymphedema sales declined and airway clearance grew 22%. Gross margin improved, but adjusted EBITDA turned negative due to tech investments. 2025 guidance was lowered for lymphedema but raised for airway clearance, with strong cash reserves and ongoing sales force expansion.
-
A $10 billion U.S. market opportunity exists for innovative lymphedema and bronchiectasis therapies, with strong financials, new product launches, and digital engagement driving growth. Strategic focus on education, access, and technology supports continued expansion.
Fiscal Year 2024
-
Q4 revenue grew 10.2% year-over-year, with strong lymphedema and airway clearance sales, improved gross margin, and robust cash generation. 2025 guidance projects 8–10% revenue growth, with investments in sales, technology, and patient access expected to drive long-term profitability.
-
Strong market fundamentals and new product launches are driving optimism for 2025, with policy changes expected to streamline patient access and support growth. The sales force is expanding and being optimized, while head and neck lymphedema trial data is anticipated in the first half of 2025.
-
Q3 revenue grew 5% year-over-year, with strong margin expansion and double-digit growth in VA and commercial lymphedema channels. 2024 revenue guidance was lowered, but EBITDA guidance was raised due to operational efficiencies and cost controls.
-
Q2 revenue grew 7% year-over-year to $73.2 million, with strong gains in lymphedema and airway clearance. 2024 revenue guidance was lowered due to Medicare documentation headwinds, but profitability and cash flow improved, and new product launches and tech investments remain on track.
-
The company is expanding its leadership in lymphedema and bronchiectasis treatment, with strong financials, new product launches, and major tech investments. Results from a landmark clinical trial and improved reimbursement for head and neck lymphedema are expected to drive growth into 2025.